News and Events - Cardionovum®

Latest press release

Mar 31, 2021

CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Trial designed to evaluate non inferiority of XLIMUS DES vs SYNERGY EES in terms of reendothelialization assessed with OCT in patients undergoing percutaneous coronary intervention

Learn more >> CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Jan 24, 2021

Two-year outcomes with the LEGFLOW DCB: primary patency maintained in real world patients.

Marc Bosiers (St. Blasius Hospital, Dendermonde, Belgium) will give an update at LINC today on the results of the REFLOW1 study, which investigated the efficacy of the LEGFLOW® drug-coated balloon (DCB) in TASC C and D femoropopliteal lesions.

Learn more >> Two-year outcomes with the LEGFLOW DCB: primary patency maintained in real world patients.

Jan 17, 2021

APERTO DCB “superior” for AV fistulae lesions in new RCT.

Professor Dr Qizhuang Jin (Peking University First Hospital Nephrology Department, China) spoke to LINC Today about the recently published results of the first randomised controlled trial (RCT) comparing the APERTO® drug-coated balloon (DCB) with high pressure angioplasty balloon in the treatment of arteriovenous fistulae (AVF) lesions.

Learn more >> APERTO DCB “superior” for AV fistulae lesions in new RCT.

Jan 10, 2021

APERTO DCB “promising” for central venous stenosis in haemodialysis patients.

In a Q&A with LINC Today, Michael Lichtenberg, angiologist at Klinikum Hochsauerland GmbH, Arnsberg, Germany, discussed the APERTO® OTW (over-the-wire) drug coated balloon (DCB) currently being trialled in haemodialysis patients with central venous stenosis (CVS) in a bid to improve patency of arteriovenous fistulas (AVFs).

Learn more >> APERTO DCB “promising” for central venous stenosis in haemodialysis patients.

May 09, 2020

Cardionovum - first transcontinental China-Europe Webinar on the treatment of complications in arteriovenous access in dialysis patients during COVID-19 pandemic.

Guest from Europe: Prof. Michael Lichtenberg (Germany) & Prof. Matteo Tozzi (Italy).

Video of European guests' speech.

Learn more >> Cardionovum - first transcontinental China-Europe Webinar on the treatment of complications in arteriovenous access in dialysis patients during COVID-19 pandemic.

Apr 20, 2020

APERTO OTW® Drug Coated Balloon receives first Chinese NMPA Medical Device Registration Certificate for High Pressure DCB for Vascular Access

APERTO®, our innovative paclitaxel coated balloon for arterio-venous access, has received market approval for China. It is the the first high pressure drug coated balloon available in China to treat obstructive lesions of native Arterio Venous Dialysis Fistulae.

The approval was given based on the statistic results from the solidly designed clinical study in Chinese population:
APERTO AVF RCT CHINA.

Learn more >> APERTO OTW® Drug Coated Balloon receives first Chinese NMPA Medical Device Registration Certificate for High Pressure DCB for Vascular Access